Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

Published:2019-09-01 Issue:9 Volume:5 Page:1276
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Theelen Willemijn S. M. E.¹,Peulen Heike M. U.²³,Lalezari Ferry⁴,van der Noort Vincent⁵,de Vries Jeltje F.⁵,Aerts Joachim G. J. V.⁶,Dumoulin Daphne W.⁶,Bahce Idris⁷,Niemeijer Anna-Larissa N.⁷,de Langen Adrianus J.¹,Monkhorst Kim⁸,Baas Paul¹

Affiliation:

1. Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam

2. Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam

3. Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands

4. Department of Radiology, Netherlands Cancer Institute, Amsterdam

5. Department of Biometrics, Netherlands Cancer Institute, Amsterdam

6. Department of Pulmonology, Erasmus Medical Center, Rotterdam, Amsterdam, the Netherlands

7. Department of Pulmonology, VU Medical Center, Amsterdam, the Netherlands

8. Department of Pathology, Netherlands Cancer Institute, Amsterdam

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2738064/jamaoncology_theelen_2019_oi_190039.pdf

Reference20 articles.

1. PD-1 and its ligands in tolerance and immunity.;Keir;Annu Rev Immunol,2008

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.;Herbst;Lancet,2016

3. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer.;Borghaei;N Engl J Med,2015

4. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer.;Reck;N Engl J Med,2016

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.;Rittmeyer;Lancet,2017

Cited by 623 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report;Frontiers in Immunology;2024-02-01

2. Review of immune checkpoint blockade and PD-L1 testing in breast cancer;Diagnostic Histopathology;2024-02

3. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer;International Immunopharmacology;2024-02

4. Radiotherapy in the management of lung oligometastases;Cancer/Radiothérapie;2024-02

5. Stereotactic body radiation therapy for liver metastases in oligometastatic disease;Cancer/Radiothérapie;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3